𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis

✍ Scribed by Jones, Rachel B.; Cohen Tervaert, Jan Willem; Hauser, Thomas; Luqmani, Raashid; Morgan, Matthew D.; Peh, Chen Au; Savage, Caroline O.; Segelmark, Mårten; Tesar, Vladimir; van Paassen, Pieter; Walsh, Dorothy; Walsh, Michael; Westman, Kerstin; Jayne, David R.W.

Book ID
126301136
Publisher
Massachusetts Medical Society
Year
2010
Tongue
English
Weight
408 KB
Volume
363
Category
Article
ISSN
0096-6762

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rituximab versus Cyclophosphamide in ANC
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
✍ Jones, Rachel B.; Cohen Tervaert, Jan Willem; Hauser, Thomas; Luqmani, Raashid; 📂 Article 📅 2010 🏛 Massachusetts Medical Society 🌐 English ⚖ 408 KB

## Background: Cyclophosphamide induction regimens for antineutrophil cytoplasmic antibody (anca)-associated vasculitis are effective in 70 to 90% of patients, but they are associated with high rates of death and adverse events. treatment with rituximab has led to remission rates of 80 to 90% among

Rituximab versus Cyclophosphamide for AN
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
✍ Stone, John H.; Merkel, Peter A.; Spiera, Robert; Seo, Philip; Langford, Carol A 📂 Article 📅 2010 🏛 Massachusetts Medical Society 🌐 English ⚖ 424 KB

## Background: Cyclophosphamide and glucocorticoids have been the cornerstone of remission-induction therapy for severe antineutrophil cytoplasmic antibody (anca)-associated vasculitis for 40 years. uncontrolled studies suggest that rituximab is effective and may be safer than a cyclophosphamide-ba

ANCA-associated renal vasculitis
ANCA-associated renal vasculitis
✍ Campo, A.; Grill, A.; Stratta, P. 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 48 KB